Pages that link to "Q83877786"
Jump to navigation
Jump to search
The following pages link to Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; A Gynecologic Oncology Group Study (Q83877786):
Displaying 16 items.
- Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer (Q33422082) (← links)
- Xeroderma pigmentosum complementation group C single‐nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression‐free survival in advanced ovarian cancer (Q33959550) (← links)
- ERCC1 and ERCC2 haplotype modulates induced BPDE-DNA adducts in primary cultured lymphocytes (Q34672604) (← links)
- Polymorphisms in ERCC1 and ERCC2/XPD genes and carcinogen DNA adducts in human lung (Q35688818) (← links)
- Emodin affects ERCC1 expression in breast cancer cells (Q36244040) (← links)
- Update on first-line treatment of advanced ovarian carcinoma (Q36571743) (← links)
- Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity (Q37136248) (← links)
- Impact of molecular profiling on overall survival of patients with advanced ovarian cancer (Q37190190) (← links)
- Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer (Q37731815) (← links)
- Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review (Q37953721) (← links)
- Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair (Q39408153) (← links)
- Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy (Q42732266) (← links)
- Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population (Q43655173) (← links)
- GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes. (Q64904916) (← links)
- Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy (Q84465873) (← links)
- FBP1 promotes ovarian cancer development through the acceleration of cell cycle transition and metastasis (Q90221302) (← links)